{"id":15551,"date":"2021-08-19T11:55:08","date_gmt":"2021-08-19T09:55:08","guid":{"rendered":"https:\/\/convergences.online\/hemato\/?p=15551"},"modified":"2021-08-19T11:55:08","modified_gmt":"2021-08-19T09:55:08","slug":"bristol-myers-squibb-receives-european-commission-approval-for-idecabtagene-vicleucel-the-first-anti-bcma-car-t-cell-therapy-for-relapsed-and-refractory-multiple-myeloma","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/bristol-myers-squibb-receives-european-commission-approval-for-idecabtagene-vicleucel-the-first-anti-bcma-car-t-cell-therapy-for-relapsed-and-refractory-multiple-myeloma\/","title":{"rendered":"Bristol Myers Squibb Receives European Commission Approval for Idecabtagene Vicleucel, the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma"},"content":{"rendered":"<p><em>Idecabtagene Vicleucel represents the only cell therapy approved for multiple myeloma <\/em><\/p>\n<p><em>Approval of Idecabtagene Vicleucel is based on the pivotal KarMMa trial of patients worldwide, including five European countries, which demonstrated rapid, deep and durable responses with a well-understood and predictable safety profile <\/em><\/p>\n<p><em>Idecabtagene Vicleucel expands upon Bristol Myers Squibb\u2019s leadership in cell therapy research and multiple myeloma, offering an innovative option to patients in need.<\/em><\/p>\n<p><em>Idecabtagene Vicleucel (ide-cel), a first-in-class B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.\u00a0 <\/em><\/p>\n<p><em>Idecabtagene Vicleucel is the first and only CAR T cell therapy approved that is directed to recognize and bind to BCMA, a protein that is nearly universally expressed on cancer cells in multiple myeloma, leading to the death of BCMA-expressing cells.1 Idecabtagene Vicleucel is delivered via a single infusion with a target dose of 420 x 106 CAR-positive viable T cells within a range of 260 to 500 x 106 CAR-positive viable T cells. Idecabtagene Vicleucel is approved for use in all European Union (EU) member states.<\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>Idecabtagene Vicleucel represents the only cell therapy approved for multiple myeloma Approval of Idecabtagene Vicleucel is based on the pivotal KarMMa trial of patients worldwide, including five European countries, which [&hellip;]<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[21],"tags":[],"ppma_author":[442],"class_list":["post-15551","post","type-post","status-publish","format-standard","hentry","category-communique-de-presse","author-marion"],"aioseo_notices":[],"authors":[{"term_id":442,"user_id":2,"is_guest":0,"slug":"marion","display_name":"HematoStat.net (M)","avatar_url":{"url":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2024\/01\/favicon-hematoStat.png","url2x":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2024\/01\/favicon-hematoStat.png"},"first_name":"HematoStat.net (M)","last_name":"","user_url":"","description":""}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15551","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=15551"}],"version-history":[{"count":0,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15551\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=15551"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=15551"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=15551"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=15551"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}